NASDAQ

Neuronetics, Inc.

STIM

5 articles

$233M Market cap · 2026-08-21

@BlueDuckCap Aug 3

BDC on X

Neuronetics, $STIM, gains backing from its largest shareholder and an activist as new management pursues a turnaround, with shareholder board nominations focused on maximizing equity value.

@BlueDuckCap Jul 24

BDC on X

$STIM https://t.co/VyAQNzsKuH

@BlueDuckCap Jul 20

BDC on X

$STIM https://t.co/OQ9UgUPoo4

@BlueDuckCap Jul 15

BDC on X

$STIM owns clinical distribution infrastructure for psychedelic treatments, while its stock price implies zero or negative equity value for the asset.

@BlueDuckCap Jul 15

BDC on X

Greenbrook TMS operates about 95 U.S. treatment centers administering Spravato and NeuroStar TMS, with more than 60,000 patients treated and 2 million treatments delivered.